[A case of prolonged remission after discontinuation of biological therapy in a patient with severe uncontrolled chronic rhinosinusitis with nasal polyps].
{"title":"[A case of prolonged remission after discontinuation of biological therapy in a patient with severe uncontrolled chronic rhinosinusitis with nasal polyps].","authors":"M A Budkovaya, S V Ryazantsev, S A Rebrova","doi":"10.17116/otorino20248906199","DOIUrl":null,"url":null,"abstract":"<p><p>Currently, targeted biological therapy is an innovative and highly effective approach in the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) associated with T2 inflammation that is uncontrolled by standard treatment methods. The article presents the first experience of long-term observation of a patient who, one year after the start of targeted biological therapy with dupilumab, independently stopped the treatment due to complete relief of symptoms of CRSwNP, despite recommendations to continue therapy to maintain control. At the same time, one year after the refusal of biological therapy, the patient showed persistent clinical remission in relation to the symptoms of CRSwNP, confirmed by the results of videoendoscopic examination of the nasal cavity and computed tomography of the sinuses. The described clinical observation emphasizes the need to develop a personalized approach to prescribing immunobiological therapy in patients with CRSwNP and a more detailed study of the criteria for a super-response to this treatment.</p>","PeriodicalId":23575,"journal":{"name":"Vestnik otorinolaringologii","volume":"89 6","pages":"99-106"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vestnik otorinolaringologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/otorino20248906199","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Currently, targeted biological therapy is an innovative and highly effective approach in the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) associated with T2 inflammation that is uncontrolled by standard treatment methods. The article presents the first experience of long-term observation of a patient who, one year after the start of targeted biological therapy with dupilumab, independently stopped the treatment due to complete relief of symptoms of CRSwNP, despite recommendations to continue therapy to maintain control. At the same time, one year after the refusal of biological therapy, the patient showed persistent clinical remission in relation to the symptoms of CRSwNP, confirmed by the results of videoendoscopic examination of the nasal cavity and computed tomography of the sinuses. The described clinical observation emphasizes the need to develop a personalized approach to prescribing immunobiological therapy in patients with CRSwNP and a more detailed study of the criteria for a super-response to this treatment.